ORILANOLIMAB ( DrugBank: Orilanolimab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 3 |
61. Autoimmune hemolytic anemia
Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-001211-90-IT (EUCTR) | 26/08/2021 | 22/10/2021 | ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo- Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA) - N/A | Warm Autoimmune Hemolytic Anemia (WAIHA) MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: ALXN1830 Product Code: [N/A] INN or Proposed INN: ORILANOLIMAB | ALEXION PHARMACEUTICALS INCORPORATED | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | France;United States;Spain;Germany;United Kingdom;Italy;Korea, Republic of | ||
| 2 | EUCTR2021-001211-90-ES (EUCTR) | 11/08/2021 | 02/07/2021 | ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA) | Warm Autoimmune Hemolytic Anemia (WAIHA) MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: ALXN1830 INN or Proposed INN: ORILANOLIMAB Other descriptive name: SYNT001 | Alexion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 2 | France;United States;Spain;Germany;United Kingdom;Italy;Korea, Republic of | ||
| 3 | EUCTR2019-004055-37-ES (EUCTR) | 06/05/2020 | 10/05/2020 | ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia | WAIHA MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: ALXN1830 INN or Proposed INN: ORILANOLIMAB Other descriptive name: SYNT001 | Alexion Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | United States;Taiwan;Spain;Russian Federation;Italy;United Kingdom;France;Canada;Belgium;Australia;Germany;Netherlands;Korea, Republic of |